|
시장보고서
상품코드
2051184
항체약물접합체(ADC) 시장 : 제품 유형별, 링커 유형별, 용도별, 판매 채널별, 지역별Antibody Drug Conjugates Market, By Product Type, By Linker Type, By Application, By Distribution Channel, By Geography |
||||||
항체약물접합체(ADC) 시장은 2026년에 80억 2,000만 달러로 추정되며, 2033년까지 205억 6,000만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 14.4%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 80억 2,000만 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간 CAGR: | 14.40% | 2033년 시장 규모 예측: | 205억 6,000만 달러 |
항체약물접합체(ADC)는 항암제를 암세포에 전달하는 표적 치료제입니다. 항체약물접합체의 작용기전(MOA)은 비교적 간단합니다. 항체약물접합체의 일부가 정맥으로 투여되고, 종양세포의 세포 표면에 있는 표적 항원에 결합하면 그 복합체가 세포 내로 흡수됩니다. 흡수된 소포는 다른 소포와 융합하여 엔도솜-리소좀 경로로 이동합니다. 리소좀 내에서는 프로테아제가 단클론항체를 분해하여 유리된 유효성분을 방출합니다. 이후 유효성분이 리소좀 막을 가로질러 세포질과 핵으로 들어가서 표적 분자에 결합하여 세포 사멸을 유발합니다.
시장 역학
시장 진입 기업들은 R&D 활동을 진행하고 있으며, 이는 예측 기간 동안 세계 항체약물접합체(ADC) 시장의 성장에 기여할 수 있습니다. 상업적 성공을 거둔 종양학 전문 생명공학 기업 엑셀릭시스(Exelixis, Inc.)는 지난 4월 5일 미국 식품의약국(FDA)이 진행성 고형암 환자에서 XB002의 안전성, 내약성, 약동학 및 예비 항종양 활성을 평가하기 위한 임상시험계획(IND)을 승인했다고 발표했습니다. 차세대 조직인자 표적 항체약물접합체(ADC)인 XB002는 기존 조직인자 표적 ADC에 비해 높은 치료 지수와 우수한 안전성 프로파일을 가질 수 있는 잠재력을 가지고 있습니다.
시장 관계자들은 전략적 제휴와 계약에 집중하고 있으며, 이는 세계 항체약물접합체(ADC) 시장의 성장을 촉진할 것으로 예상됩니다. 예를 들어, 2022년 6월 17일, 세계적인 연구개발형 제약기업인 에자이와 세계적인 바이오제약기업인 브리스톨 마이어스 스퀴브(Bristol-Myers Squibb)는 항체약물접합체(ADC) MORAb-202의 공동 개발 및 공동 상업화에 대한 세계 독점적 전략적 제휴 계약을 체결하였다고 발표하였습니다.
시장 기업과 정부 당국은 인수 및 제휴와 같은 전략을 채택하여 세계 입지를 확대하고 있으며, 이는 세계 항체약물접합체(ADC) 시장의 성장을 견인할 것으로 예상됩니다. 예를 들어, 2021년 9월 13일, 연구 개발형 바이오의약품 기업인 길리어드 사이언스(Gilead Sciences)와 차세대 항체약물접합체(ADC) 기술의 선두주자인 이뮤노메딕스(Immunomedics)는 길리어드 사이언스가 이뮤노메딕스를 주당 88달러의 현금으로 인수한다는 최종 합의를 발표했습니다. 합의 조건에 따라 길리어드는 2021년 4월 미국 식품의약국(FDA)으로부터 전이성 삼중음성 유방암(mTNBC) 성인 환자 치료제로 신속 승인을 획득한, Trop-2를 표적으로 하는 퍼스트-인-클래스 항체약물접합체(ADC)인 '트로델비(sacituzumab govitecan-hziy)'를 확보하게 됩니다.
본 조사의 주요 특징
- 이 보고서는 다양한 부문의 잠재적 수익 창출 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 지역별 전망, 주요 기업의 경쟁 전략에 대한 중요한 인사이트도 제공합니다.
- 이 보고서에서는 회사 개요, 재무 실적, 제품 포트폴리오, 사업 지역, 유통 전략, 주요 개발 및 전략, 향후 계획 등 다양한 매개 변수를 기반으로 세계 항체약물접합체(ADC) 시장의 주요 기업 프로파일을 작성했습니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 기술 업그레이드, 시장 확대 및 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것으로 기대됩니다.
- 이 세계 항체약물접합체(ADC) 시장 보고서는 투자자, 공급업체, 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 항체약물접합체 시장 분석에 사용되는 다양한 전략 매트릭스를 활용하여 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 항체약물접합체(ADC) 시장 : 제품 유형별, 2021-2033년
제5장 세계의 항체약물접합체(ADC) 시장 : 링커 유형별, 2021-2033년
제6장 세계의 항체약물접합체(ADC) 시장 : 용도별, 2021-2033년
제7장 세계의 항체약물접합체(ADC) 시장 : 유통 채널별, 2021-2033년
제8장 세계의 항체약물접합체(ADC) 시장 : 지역별, 2021-2033년
제9장 경쟁 구도
제10장 섹션
KSM 26.06.16Antibody Drug Conjugates Market is estimated to be valued at USD 8.02 Bn in 2026 and is expected to reach USD 20.56 Bn by 2033, growing at a compound annual growth rate (CAGR) of 14.4% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 8.02 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 14.40% | 2033 Value Projection: | USD 20.56 Bn |
Antibody Drug Conjugates (ADCs) are targeted medicines that deliver chemotherapy drugs to cancer cells. The mechanism of action (MOA) of antibody-drug conjugates is fairly straightforward. When a portion of the antibody-drug conjugate is administered intravenously and binds to a target antigen on the cell surface of the tumor cell, the complex is internalized. Internalized vesicles fuse with other vesicles and enter the endosome-lysosome pathway after internalization. In the lysosome, proteases digest the monoclonal antibody to release free payloads, which then cross the lysosome membrane to enter the cytoplasm and/or nucleus, where they bind to the target molecule, causing cell death.
Market Dynamics
Market players are involved in research and development activities, this could contribute to the growth of the global antibody drug conjugates market over the forecast period. For instance, on April 05, 2022, Exelixis, Inc., a commercially successful oncology-focused biotechnology company, announced that the U.S. Food and Drugs Administration (FDA) accepted their Investigational New Drug Application (IND) to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of XB002 in patients with advanced solid tumors. XB002, as a next-generation tissue factor-targeting antibody-drug conjugate (ADC), has the potential for a higher therapeutic index and a better safety profile than earlier-generation tissue factor-targeting ADCs.
Market players are focused on strategic collaborations and agreements, which is expected to propel the growth of the global antibody drug conjugates market. For instance, on June 17, 2022, Eisai Co., Ltd., a leading global R&D-based pharmaceutical company, and Bristol-Myers Squibb Company, a global biopharmaceutical company, announced an exclusive global strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody drug conjugate (ADC).
Market players and government authorities are involved in expanding their global presence by adopting strategies such as acquisitions and collaborations, which is expected to drive the growth of the global antibody drug conjugates market. For instance, on September 13, 2021, Gilead Sciences, Inc., a research-based biopharmaceutical company, and Immunomedics, a leader in next-generation antibody-drug conjugate (ADC) technology, announced a definitive agreement under which Gilead will acquire Immunomedics for US$ 88.00 per share in cash. Under the terms of agreement, Gilead will be provided with Trodelvy (sacituzumab govitecan-hziy), a first-in-class Trop-2 directed antibody-drug conjugate (ADC) that was granted accelerated approval by the U.S. Food and Drug Administration (FDA) in April 2021, for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC).
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
- It profiles leading players in the global antibody drug conjugates market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
- Key companies covered as a part of this study include Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline Plc, Takeda Pharmaceutical Company Ltd., Astellas Pharma, ADC Therapeutics, Pfizer, Inc., Seagen, Inc., Daiichi Sankyo Company Ltd., and Oxford Biotherapeutics.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
- The global antibody drug conjugates market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global antibody drug conjugates market
Market Segmentation
- Product Type Insights (Revenue, USD Bn, 2026 - 2033)
- Adcetris
- Kadcyla
- Enhertu
- Trodelvy
- Padcev
- Others
- Linker Type Insights (Revenue, USD Bn, 2026 - 2033)
- Non-cleavable Linker
- Cleavable Linker
- Application Insights (Revenue, USD Bn, 2026 - 2033)
- Blood Cancer
- Breast Cancer
- Ovary Cancer
- Lung Cancer
- Skin Cancer
- Brain Tumor
- Others
- Distribution Channel Insights (Revenue, USD Bn, 2026 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- E-commerce
- Regional Insights (Revenue, USD Bn, 2026 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- South Africa
- Rest of Middle East & Africa
- Key Players Insights
- AstraZeneca PLC
- Daiichi Sankyo Company Limited
- Novasep
- ADC Therapeutics SA
- Alentis Therapeutics AG
- F. Hoffmann-La Roche
- Gilead Sciences, Inc.
- AbbVie Inc.
- Biosion USA, Inc.
- Astellas Pharma Inc.
- Duality Biologics (Suzhou) Co. Ltd.
- BioNTech SE
- LaNova Medicines Ltd.
- Bliss Biopharmaceutical
- Eisai Co., Ltd.
- ProfoundBio
- Pfizer, Inc.
- ImmunoGen Inc.
- Mersana Therapeutics Inc.
- Sorrento Therapeutics Inc.
- Oxford BioTherapeutics Ltd
- Takeda Pharmaceutical Company Ltd
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Product Type
- Market Snippet, By Linker Type
- Market Snippet, By Application
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Product Launches
- Epidemiology
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
4. Global Antibody Drug Conjugates Market, By Product Type, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Adcetris
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
- Kadcyla
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
- Besponsa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
- Lumoxiti
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
- Mylotarg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
- Others (Polivy, Lumoxiti, Zynlonta, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
5. Global Antibody Drug Conjugates Market, By Linker Type, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Non-Cleavable Linker
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
- Cleavable Linker
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
6. Global Antibody Drug Conjugates Market, By Application, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Blood Cancer
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Breast Cancer
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Ovary Cancer
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Lung Cancer
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Skin Cancer
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Brain Tumor
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Others
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
7. Global Antibody Drug Conjugates Market, By Distribution Channel , 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- E-commerce
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
8. Global Antibody Drug Conjugates Market, By Region, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Product Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Linker Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Application, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel , 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 - 2033, (US$ Bn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Product Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Linker Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Application, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel , 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 - 2033, (US$ Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Product Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Linker Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Application, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel , 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 - 2033, (US$ Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Product Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Linker Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Application, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel , 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 - 2033, (US$ Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Product Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Linker Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Application, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel , 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 - 2033, (US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Product Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Linker Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Application, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel , 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 - 2033, (US$ Bn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Company Profiles
- AstraZeneca PLC
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Daiichi Sankyo Company, Limited
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Novasep
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- ADC Therapeutics SA
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Alentis Therapeutics AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- F. Hoffmann-La Roche
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Gilead Sciences, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- AbbVie Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Biosion USA, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Astellas Pharma Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Duality Biologics (Suzhou) Co. Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- BioNTech SE
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- LaNova Medicines Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Bliss Biopharmaceutical
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Eisai Co., Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- ProfoundBio
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Pfizer, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- ImmunoGen Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Mersana Therapeutics Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Sorrento Therapeutics Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Oxford BioTherapeutics Ltd
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Takeda Pharmaceutical Company Ltd
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- AstraZeneca PLC
10. Section
- References
- Research Methodology
- About us and Sales Contact
